Clinical trials diversity is one of the most pressing challenges in modern medical research. Clinical trials are the primary method used to evaluate the safety and effectiveness of new treatments in people, including medicines, medical devices, procedures, and lifestyle interventions such as changes in diet or exercise. Every medical treatment must pass through clinical trials before the FDA approves it for public use. Yet despite this universal requirement, the populations enrolled in these trials often do not reflect the full diversity of the patients who will eventually use the treatments being tested.<\/p>\n
The need for clinical trials diversity is not a matter of preference. It is a scientific necessity rooted in the biological reality that people respond differently to treatments based on age, sex, genetics, lifestyle, and comorbid conditions.<\/p>\n
A widely cited example involves a medication developed to treat heart failure that was found to work significantly better in African American patients than in Caucasian patients. This difference was attributable to genetic variation between the two groups. Without diverse trial enrollment, this distinction would never have been detected, and patients who could have benefited most from the treatment might never have received it.<\/p>\n
The stakes are even clearer in oncology. African American men are twice as likely to die from prostate cancer as Caucasian men, yet represent only 4% of prostate cancer clinical trial participants. This gap means that the research most needed for a population at highest risk is being conducted almost entirely without their participation.<\/p>\n
The data on clinical trials diversity is stark. The National Institutes of Health, the FDA, and numerous other organizations have consistently documented that minorities are underrepresented in clinical research. Racial and ethnic minorities represent nearly 4 out of every 10 people in the United States, yet their enrollment in clinical trials falls far short of that proportion.<\/p>\n
Additional figures underscore the scale of the problem. Fewer than 2% of more than 10,000 NIH funded cancer clinical trials included enough minority participants to meet the agency’s own goals. Fewer than 5% of NIH funded research into respiratory diseases reported including racial and ethnic minorities. And while the health consequences of HIV are disproportionately severe among African American women, clinical trials for potential HIV treatments enrolled predominantly white men.<\/p>\n
Multiple barriers limit minority enrollment in clinical research. Limited access to care centers that serve as referral sources for trials creates a structural gap that affects communities before they ever have the opportunity to participate. Physician bias and a general distrust of medical institutions, grounded in a documented history of exploitation and unethical research practices, continue to deter participation from communities that have the most reason to be skeptical.<\/p>\n
Cultural and language barriers prevent many potential participants from fully understanding the trials they are being asked to join. Late stage diagnoses in many minority communities mean that patients are often too ill by the time they are identified to meet trial eligibility criteria. And concerns about exploitation, even in the absence of specific prior experience, remain a persistent obstacle across multiple demographic groups.<\/p>\n
The FDA has established three specific goals to address the clinical trials diversity gap. First, improving the completeness and quality of demographic subgroup data collection, reporting, and analysis. Second, identifying barriers to enrollment and implementing strategies to increase participation from underrepresented groups. Third, making demographic subgroup data more widely available and transparent so that gaps are visible and addressable.<\/p>\n
These goals place the responsibility squarely on research organizations, sponsors, and CROs to design studies that actively reach diverse populations rather than defaulting to the path of least resistance.<\/p>\n
Clinical trials diversity is not a secondary consideration at FOMAT. It is central to our identity as an Embedded Research Organization. Our investigator network is deliberately built in communities that have historically been excluded from clinical research, and our patient recruitment approach prioritizes cultural relevance, language accessibility, and the removal of logistical barriers that prevent underrepresented populations from enrolling.<\/p>\n
We partner with sponsors and CROs who share our commitment to building research programs that reflect the real world diversity of the patients those programs are meant to serve. To learn more about our diversity capabilities<\/a> or explore our active studies<\/a>, visit fomatmedical.com.<\/p>\n